A New Wave in Depression Treatment: GlyphAllo Enters Phase 2b for MDD With and Without Anxious Distress

For decades, we've grappled with the challenge of treating major depressive disorder (MDD)—particularly in clients who also experience anxious distress. Add to that the limitations of current treatments, delayed onset of action, and tolerability issues, and it’s no wonder that innovation in this space is urgently needed

Newest Psychiatric Treatments for Generalized Anxiety Disorder (GAD)

There are few drugs that are Food and Drug Administration (FDA) indicated first line for Generalized Anxiety Disorder (GAD). Selective Serotonin Inhibitors (SSRIs) such as Lexapro (escitalopram), approved in 2005, and Paxil (paroxetine), approved in 1999, by the FDA.

Caplyta in Bipolar Depression: When Efficacy Meets Tolerability

The conversation around lumateperone (Caplyta) in bipolar depression has become more nuanced with new data and, frankly, more complicated in clinical practice. A recent meta-analysis in the Journal of Psychopharmacology confirmed what many of us already knew at the bedside:

GM-2505: A Promising Advancement in the Treatment of Major Depressive Disorder

A Deep Dive Into GLP-1 Medication for Weight Loss

GLP-1 medications are an effective tool for weight loss, especially when combined with dietary and behavioral changes. These drugs mimic a natural gut hormone, GLP-1, released after eating to help regulate appetite, digestion, and blood sugar. While digestive side effects are common, serious complications are rare but should be monitored.

Should We Worry About Ileus with Pines and Cobenfy? Reconsidering the Risk

As the psychiatric community continues to explore Cobenfy (xanomeline/trospium chloride) as a novel option in the treatment of schizophrenia, questions have emerged regarding its safety when used in combination with antipsychotics from the “-pine” family—such as clozapine, olanzapine, and quetiapine.